State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines

Charlene M. Dawidczyk, Chloe Kim, Jea Ho Park, Luisa M. Russell, Kwan Hyi Lee, Martin G. Pomper, Peter C. Searson

Research output: Contribution to journalReview article

Abstract

The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide an important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs.

Original languageEnglish (US)
Pages (from-to)133-144
Number of pages12
JournalJournal of Controlled Release
Volume187
DOIs
StatePublished - Aug 10 2014

Keywords

  • Active targeting
  • Circulation
  • Enhanced permeability and retention (EPR) effect
  • Liposomes
  • Nanoparticles
  • Tumor targeting

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines'. Together they form a unique fingerprint.

Cite this